Commonwealth Equity Services LLC lowered its holdings in Sanofi SA (NYSE:SNY) by 7.5% in the first quarter, Holdings Channel reports. The firm owned 113,366 shares of the company’s stock after selling 9,161 shares during the period. Commonwealth Equity Services LLC’s holdings in Sanofi were worth $5,019,000 as of its most recent SEC filing.
Other institutional investors and hedge funds have also modified their holdings of the company. Claybrook Capital LLC purchased a new position in Sanofi in the fourth quarter valued at about $31,000. Executive Wealth Management LLC purchased a new position in Sanofi in the fourth quarter valued at about $34,000. Nkcfo LLC bought a new position in Sanofi during the 1st quarter worth approximately $35,000. Cullen Frost Bankers Inc. bought a new position in Sanofi during the 1st quarter worth approximately $35,000. Finally, Howe & Rusling Inc. bought a new position in Sanofi during the 1st quarter worth approximately $38,000. 7.04% of the stock is owned by hedge funds and other institutional investors.
NYSE:SNY opened at $42.68 on Friday. The company has a debt-to-equity ratio of 0.40, a quick ratio of 0.85 and a current ratio of 1.22. Sanofi SA has a 52 week low of $38.95 and a 52 week high of $45.62. The company has a market cap of $107.09 billion, a price-to-earnings ratio of 13.64, a PEG ratio of 2.41 and a beta of 0.67.
Sanofi (NYSE:SNY) last released its earnings results on Friday, April 26th. The company reported $0.81 EPS for the quarter, topping analysts’ consensus estimates of $0.74 by $0.07. Sanofi had a return on equity of 18.18% and a net margin of 12.20%. The company had revenue of $8.39 billion for the quarter, compared to the consensus estimate of $8.34 billion. During the same quarter last year, the business posted $1.28 EPS. Sanofi’s quarterly revenue was up 6.2% compared to the same quarter last year. On average, research analysts forecast that Sanofi SA will post 3.1 earnings per share for the current fiscal year.
Separately, HC Wainwright reaffirmed a “buy” rating on shares of Sanofi in a report on Thursday, February 28th. Eight investment analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and an average target price of $51.00.
TRADEMARK VIOLATION WARNING: “Commonwealth Equity Services LLC Has $5.02 Million Position in Sanofi SA (NYSE:SNY)” was posted by Stock Observer and is the sole property of of Stock Observer. If you are reading this piece of content on another site, it was stolen and reposted in violation of United States and international copyright & trademark law. The original version of this piece of content can be accessed at https://www.thestockobserver.com/2019/06/14/commonwealth-equity-services-llc-has-5-02-million-position-in-sanofi-sa-nysesny.html.
Sanofi provides therapeutic solutions. It offers Cerezyme and Cerdelga for Gaucher disease, Myozyme and Lumizyme for Pompe disease, Fabrazyme for Fabry disease, and Aldurazyme for mucopolysaccharidosis Type 1; Aubagio, an immunomodulatory; and Lemtrada, a monoclonal antibody to treat multiple sclerosis.
Want to see what other hedge funds are holding SNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sanofi SA (NYSE:SNY).
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.